- Once-Yearly Lenacapavir Looks Promising for HIV PrEP POZ
- Scientists develop yearly HIV injection: How it could help millions The Times of India
- Lenacapavir plus broadly neutralising antibodies could be twice-yearly HIV treatment aidsmap
- Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals The Financial Express
- Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study The Lancet
Once-Yearly Lenacapavir Looks Promising for HIV PrEP POZScientists develop yearly HIV injection: How it could help millions The Times of IndiaLenacapavir plus broadly neutralising antibodies could be twice-yearly HIV treatment aidsmapGilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals The Financial ExpressPharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study The Lancet Top stories – Google News